{"classes":[{"categories":[{"measurements":[{"comment":"Participants were not evaluable per International Myeloma Working Group (IMWG) uniform response criteria","groupId":"OG000","value":"NA"},{"comment":"Participants were not evaluable per International Myeloma Working Group (IMWG) uniform response criteria","groupId":"OG001","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"}],"units":"Participants"}],"description":"Determined by International Myeloma Working Group (IMWG) uniform response criteria.\n\nCR: Negative immunofixation of serum and urine, disappearance of any soft-tissue plasmacytomas, and \\<5% plasma cells in bone marrow; in patients for whom only measurable disease is by serum free light chain (FLC) level, normal FLC ratio of 0.26 to 1.65 in addition to CR criteria is required; 2 consecutive assessments are needed.\n\nVGPR: Serum and urine M-component detectable by immunofixation but not on electrophoresis or ≥90% reduction in serum M-component plus urine M-component \\<100 mg/24 hours (hrs); in patients for whom only measurable disease is by serum FLC level, \\>90% decrease in difference between involved and uninvolved FLC levels, in addition to VGPR criteria, is required; 2 consecutive assessments are needed","groups":[{"description":"Participants received 33 kiloBecquerel (kBq)/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses in combination with BOR and DEX","id":"OG000","title":"Radium-223 Dichloride 33 kBq/kg + Bortezomib and Dexamethasone"},{"description":"Participants received 55 kBq/kg body weight every 6 weeks for a total of 6 radium-223 dichloride doses in combination with BOR and DEX","id":"OG001","title":"Radium-223 Dichloride 55 kBq/kg + Bortezomib and Dexamethasone"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The safety analysis set including all participants who received at least one administration of study treatment","reportingStatus":"POSTED","timeFrame":"Up to approximately 2 years","title":"Phase 1: The Number of Subjects With Complete Response (CR) and Very Good Partial Response (VGPR)","type":"SECONDARY","unitOfMeasure":"Participants"}